MedPath

Taejoon Pharmaceutical Co., Ltd.

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

13

Active:0
Completed:8

Trial Phases

4 Phases

Phase 1:2
Phase 2:1
Phase 3:8
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 3
8 (61.5%)
Phase 1
2 (15.4%)
Phase 4
2 (15.4%)
Phase 2
1 (7.7%)

Comparing Efficacy and Safety of CTO0303 in Pediatric Subjects

Phase 2
Recruiting
Conditions
Pupillary Dilation Effect During Cycloplegic Refraction
Interventions
Drug: CTO0303-B
Drug: CTO0303-C
Drug: CTO0303-A
First Posted Date
2024-09-24
Last Posted Date
2024-09-24
Lead Sponsor
Taejoon Pharmaceutical Co., Ltd.
Target Recruit Count
156
Registration Number
NCT06609525
Locations
🇰🇷

Gachon University Gil Medical Center, Incheon, Korea, Republic of

Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients

Phase 3
Completed
Conditions
Dry Eye
Dry Eye Syndromes
Interventions
First Posted Date
2024-05-23
Last Posted Date
2025-04-22
Lead Sponsor
Taejoon Pharmaceutical Co., Ltd.
Target Recruit Count
271
Registration Number
NCT06427031
Locations
🇰🇷

Taejoon Pharmaceutical Co., Ltd., Seoul, Korea, Republic of

A Phase 3 Clinical Trials for Bowel Preparation for Colonoscopy

Phase 3
Completed
Conditions
Bowel Preparation
Interventions
Drug: CTP0302-B
Drug: CTP0302-A
Drug: Conventional OST
First Posted Date
2024-03-01
Last Posted Date
2024-11-28
Lead Sponsor
Taejoon Pharmaceutical Co., Ltd.
Target Recruit Count
161
Registration Number
NCT06287606
Locations
🇰🇷

Taejoon Pharmaceutical Co., Ltd., Seoul, Korea, Republic of

A Phase 3 Trial in Bowel Preparation for Colonoscopy

Phase 3
Completed
Conditions
Bowel Preparation
Interventions
Drug: CTP0301-B
Drug: CTP0301-A
Drug: Cool prep
First Posted Date
2023-05-23
Last Posted Date
2024-02-28
Lead Sponsor
Taejoon Pharmaceutical Co., Ltd.
Target Recruit Count
137
Registration Number
NCT05870553
Locations
🇰🇷

Taejoon Pharmaceutical Co., Ltd., Seoul, Korea, Republic of

A Prospective, Randomized, Investigator-blinded, Parallel, Multi-center, Phase 3 Trial

Phase 3
Completed
Conditions
Bowel Preparation
Interventions
Drug: Orafang Tab
First Posted Date
2023-01-04
Last Posted Date
2023-03-01
Lead Sponsor
Taejoon Pharmaceutical Co., Ltd.
Target Recruit Count
84
Registration Number
NCT05670470
Locations
🇰🇷

Kyung Hee University Hospital at Gangdong, Seoul, Gangdong, Korea, Republic of

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.